NCT04249947View on ClinicalTrials.gov

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

PHASE1TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 28, 2020

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Prostatic Neoplasms, Castration-ResistantNeoplasms by Histologic TypeNeoplasms, ProstateProstate CancerMetastatic Castration-resistant Prostate CancerNeoplasmsProstatic NeoplasmsGenital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteProstatic DiseaseSalivary Gland CancerSalivary Gland TumorAdenoid Cystic CarcinomaSalivary Duct CarcinomaMucoepidermoid CarcinomaAcinic Cell Tumor
Interventions
BIOLOGICAL

P-PSMA-101 CAR-T cells

P-PSMA-101 is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target prostate cancer cells expressing the cell surface antigen prostate-specific membrane antigen (PSMA).

DRUG

Rimiducid

Rimiducid (safety switch activator) may be administered as indicated

Trial Locations (10)

10065

Memorial Sloan Kettering Cancer Center, New York

21201

University of Maryland, Baltimore, Baltimore

37203

Tennessee Oncology, Nashville

70112

Tulane University Hospital and Clinic, New Orleans

80218

Sarah Cannon Research Institute at HealthONE, Denver

91010

City of Hope Comprehensive Cancer Center, Duarte

92093

University of California San Diego, San Diego

94143

University of California San Francisco, San Francisco

02215

Dana-Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Poseida Therapeutics, Inc.

INDUSTRY

NCT04249947 - P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | Biotech Hunter | Biotech Hunter